Drug Trial Radar · NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
675
Planned (sponsor's estimate)
Start
Jan 9, 2025
Primary completion
Jan 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- BlossomHill TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643, both as a monotherapy and in combination with chemotherapy. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643Drug
BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets. Subjects will take BH-30643 orally depending on their dose level assignment.
BH-30643 combo therapy with Carboplatin/PemetrexedDrug
BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets in combo therapy with Carboplatin/Pemetrexed. Subjects will take BH-30643 orally depending on their dose level assignment. Carboplatin/Pemetrexed will be administered according to standard of care
BH-30643Drug
BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)Time frame: Within the first 21 days of the first dose of BH-30643.
- Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)Time frame: Within 21 days of last participant dosed during Dose Expansion/Optimization.
- Objective Response Rate (ORR) (Phase 2)Time frame: Approximately 3 years after the first participant dosed.
Locations
43 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital - Arizona
Phoenix, Arizona · Recruiting
The Regents of the University of California - Irvine, CA Campus
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Cedars-Sinai Cancer at Cedars Sinai Medical Center
Los Angeles, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Stanford University Medical Center
Stanford, California · Recruiting
Yale University - Cancer Center
New Haven, Connecticut · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic - Florida
Jacksonville, Florida · Recruiting
Sarah Cancer Research Institution - Florida Cancer Specialist
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
Mayo Clinic Hospital - Rochester, MN
Rochester, Minnesota · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute, LLC
Nashville, Tennessee · Recruiting
The University of Texas - M.D. Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Prince of Wales Hospital
Shatin, New Territories, Hong Kong · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Kindai University Hospital
Osakasayama-shi, Osaka, Japan · Recruiting
National Cancer Center Hospital
Tsukiji, Tokyo, Japan · Recruiting
Sarawak General Hospital
Kuching, Sarawak, Malaysia · Recruiting
National University Hospital
Kent Ridge, Singapore · Recruiting
National Cancer Centre - Singapore
Singapore, Singapore · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.